Cardiogenic shock teams again tied to lower mortality
September 23, 2021
New data suggest centers with a shock team had higher survival and lower resource use in the cardiac ICU.
Two swings, two misses with colchicine, Vascepa in COVID-19
September 1, 2021
The study cohorts varied from healthcare and public workers at high risk for infection to individuals already hospitalized with COVID-19.
Dapagliflozin in HFrEF may cut arrhythmias, sudden death: DAPA-HF
August 27, 2021
Response to the positive findings was tempered, however, by the post hoc nature of the analysis, choice of primary outcome, and inconsistencies between key subgroups.
Reversal agents curb DOAC-related bleeding but deaths still high
June 17, 2021
The meta-analysis of more than 4,000 patients also showed thrombotic events were more frequent with andexanet than with 4PCC or idarucizumab.
First risk score to predict bleeding risk after TAVR
June 11, 2021
PREDICT-TAVR was developed and validated in two national registries in Europe and outperformed existing risk scores developed outside TAVR.
Single subcutaneous shot offers fast, potent platelet inhibition in STEMI
June 1, 2021
The effect was seen within 15 minutes of receiving RUC-4, an investigational glycoprotein IIb/IIIa inhibitor, with no thrombocytopenia, in a phase 2a study.
Higher MI shock survival with NCSI protocol: Final results
April 30, 2021
Final results of the National Cardiogenic Shock Initiative show better survival rates in acute MI shock than seen in previous North American studies, but 1-year mortality remains a problem.
Arthritis drug may curb myocardial damage in acute STEMI
April 13, 2021
Tocilizumab appears to improve myocardial salvage by helping tamp down the inflammatory overshoot that occurs during infarction and reperfusion.
ApoB may better predict mortality risk in statin-treated patients
March 24, 2021
In the study, measures of apoB and non-HDL cholesterol, but not LDL cholesterol, were associated with increased residual mortality and myocardial infarction risk.
RECOVERY trial of COVID-19 treatments stops colchicine arm
March 8, 2021
Recruitment was halted for lack of efficacy in patients hospitalized with the disease.